Literature DB >> 20601976

Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.

Muhammad Hanif1, Alexey A Nazarov, Christian G Hartinger, Wolfgang Kandioller, Michael A Jakupec, Vladimir B Arion, Paul J Dyson, Bernhard K Keppler.   

Abstract

The synthesis and in vitro anticancer activity of Os(II)-arene complexes with carbohydrate-derived phosphite co-ligands are reported. The compounds were characterized by standard methods and the molecular structure of dichlorido(eta(6)-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-alpha-D-glucofuranoside)osmium(II) was determined by X-ray diffraction analysis. Complexes with chlorido leaving groups undergo hydrolysis by consecutive formation of aqua compounds, followed by cleavage of a P-O bond of sugar phosphite ligands, as demonstrated by NMR studies. These observations are similar to those of analogous Ru(II)-arene complexes; however the rate of hydrolysis is very slow for osmium compounds. The complexes with oxalato leaving groups resist hydrolysis; no hydrolytic species were detected by (31)P{(1)H} NMR spectroscopy over several days. Within this series of Os compounds, in vitro anticancer activity is highest for the most lipophilic chlorido complex dichlorido(eta(6)-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-alpha-D-glucofuranoside)osmium(II).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601976     DOI: 10.1039/c003085f

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  12 in total

Review 1.  Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies.

Authors:  Mehvash Zaki; Suboot Hairat; Elham S Aazam
Journal:  RSC Adv       Date:  2019-01-24       Impact factor: 4.036

2.  Polynuclear ruthenium organometallic complexes containing a 1,3,5-triazine ligand: synthesis, DNA interaction, and biological activity.

Authors:  Floyd A Beckford; Madison B Niece; Brittany P Lassiter; Stephen J Beebe; Alvin A Holder
Journal:  J Biol Inorg Chem       Date:  2018-07-23       Impact factor: 3.358

3.  Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways.

Authors:  Kogularamanan Suntharalingam; Timothy C Johnstone; Peter M Bruno; Wei Lin; Michael T Hemann; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2013-09-16       Impact factor: 15.419

4.  A comparative DFT study on aquation and nucleobase binding of ruthenium (II) and osmium (II) arene complexes.

Authors:  Hanlu Wang; Xingye Zeng; Rujin Zhou; Cunyuan Zhao
Journal:  J Mol Model       Date:  2013-09-15       Impact factor: 1.810

5.  Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity.

Authors:  Lukas K Filak; Gerhard Mühlgassner; Felix Bacher; Alexander Roller; Markus Galanski; Michael A Jakupec; Bernhard K Keppler; Vladimir B Arion
Journal:  Organometallics       Date:  2010-12-27       Impact factor: 3.876

6.  Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.

Authors:  Adam J Millett; Abraha Habtemariam; Isolda Romero-Canelón; Guy J Clarkson; Peter J Sadler
Journal:  Organometallics       Date:  2015-03-25       Impact factor: 3.876

7.  Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.

Authors:  Gabriel E Büchel; Anatolie Gavriluta; Maria Novak; Samuel M Meier; Michael A Jakupec; Olesea Cuzan; Constantin Turta; Jean-Bernard Tommasino; Erwann Jeanneau; Ghenadie Novitchi; Dominique Luneau; Vladimir B Arion
Journal:  Inorg Chem       Date:  2013-05-09       Impact factor: 5.165

8.  Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes.

Authors:  Muhammad Hanif; Samuel M Meier; Alexey A Nazarov; Julie Risse; Anton Legin; Angela Casini; Michael A Jakupec; Bernhard K Keppler; Christian G Hartinger
Journal:  Front Chem       Date:  2013-10-31       Impact factor: 5.221

Review 9.  Metal complexes in cancer therapy - an update from drug design perspective.

Authors:  Umar Ndagi; Ndumiso Mhlongo; Mahmoud E Soliman
Journal:  Drug Des Devel Ther       Date:  2017-03-03       Impact factor: 4.162

10.  Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction.

Authors:  Chao Yang; Wanhe Wang; Guo-Dong Li; Hai-Jing Zhong; Zhen-Zhen Dong; Chun-Yuen Wong; Daniel W J Kwong; Dik-Lung Ma; Chung-Hang Leung
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.